IDH2 and acute myeloid leukemia: We present here the results of the GIMEMA AML1516 protocol, designed to (i) study the prevalence of IDH1 and IDH2 mutations in patients with AML at the time of initial diagnosis and at relapse, (ii) evaluate the association between IDH mutations and patient or disease characteristics, and (iii) assess the impact on response to treatment and survival.